Please assess the completion status of the following clinical trial:

Trial Title: PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion criteria for Aim 1:~* Scheduled to receive therapy with trastuzumab plus chemotherapy as part of standard care~* Have one or more breast tumors visualized by conventional PET/CT, CT or magnetic resonance imaging (MRI) prior to the PET FMAU study; PET/CT should be within a week prior to 18-F FMAU~Inclusion criteria for Aim 2:~* Have been diagnosed with a HER2+ invasive cancer of the breast~* Scheduled to receive pre-operative therapy with trastuzumab plus chemotherapy as part of standard care~* Have one or more breast tumors visualized by conventional PET/CT, CT or MRI prior to the PET FMAU study; PET/CT should be within a week prior to 18-F FMAU~Exclusion Criteria:~* Have undergone chemotherapy or radiation therapy within the previous one month~* Women of childbearing potential, unless they have had a negative urine human chorionic gonadotropin (HCG) within the previous 24 hours of the procedure~* Patients who have had surgery at the site of the suspected lesion within 1 month

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (fluorine F 18-clevudine PET/CT) (Type: EXPERIMENTAL): Patients receive fluorine F18-clevudine IV over 1 minute and then undergo PET/CT scan at baseline. Patients with HER2+ breast cancer also undergo fluorine F 18-clevudine PET/CT scan 2-3 weeks after the first course of treatment and after completion of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).